// App-Quantinova.ai

O-305 : SPIRIT long-term extension study: two-year efficacy and safety of relugolix combination therapy in women with endometriosis-associated pain

Researchers

Presenter

  • C Becker

Principal Investigators

  • S As-Sanie

  • M.S Abrao

  • E Brown

  • J.C Arjona Ferreira

  • R.B Wagman

  • F Wang

  • J.S Perry

  • N Johnson

  • L.C Giuduce

Medical Centers

  • São Paulo University, Ob/Gyn, São Paulo, Brazil

  • University of Michigan Medical Center, Obstetrics and Gynecology, Michigan, U.S.A

  • Medi-Sense- Inc.-, Medi-Sense- Inc.-, Atlanta- Georgia, U.S.A

  • University of California San Francisco, Department of Obstetrics- Gynecology and Reproductive Sciences, San Francisco- California, U.S.A

  • Myovant Sciences Inc., Myovant Sciences Inc., Brisbane- California, U.S.A

  • University of Adelaide, Robinson Research Institute, Adelaide, Australia

  • University of Oxford, Nuffield Department of Women’s and Reproductive Health, Oxford, United Kingdom

Locations

  • Brazil

  • United States

  • Georgia

  • Australia

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Obstetrics/Gynecology

Disease

  • Endometriosis

Biomarkers

  • Bone Mineral Density

  • Nutritional risk screening

Drug/Treatment

  • Norethisterone acetate

  • Alora

  • relugolix

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Open Label

  • Single Arm

  • Multinational

  • Controlled

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved